Topics

Sobi invests $915m in Dova and its hematology portfolio

11:14 EDT 3 Oct 2019 | in-PharmaTechnologis

Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.

Original Article: Sobi invests $915m in Dova and its hematology portfolio

NEXT ARTICLE

More From BioPortfolio on "Sobi invests $915m in Dova and its hematology portfolio"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...